Literature DB >> 7683872

Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.

P S Turk1, J F Belliveau, J W Darnowski, M C Weinberg, L Leenen, H J Wanebo.   

Abstract

Previously irradiated recurrent pelvic malignancy is refractory to most treatment modalities. Ten patients with local recurrences (six with rectal cancer; three, anal cancer; and one, anorectal melanoma) were treated with a total of 17 courses of isolated pelvic perfusion chemotherapy (12 with multiple agents) using standard hemodialysis technology. Aortic and inferior vena caval occlusion was maintained via transfemoral balloon catheters, with a single intraoperative balloon disruption. Mean pelvic-systemic drug exposure ratios were 9.8:1 for fluorouracil, 4.8:1 for cisplatin, and 4.4:1 for mitomycin C. Results were three partial responses (two patients subsequently underwent resection) and three minor responses, all in patients with a visible tumor. Pelvic pain was relieved in six of eight symptomatic patients (mean duration, 4 months). Using limited access, this procedure produces high pelvic-systemic concentration gradients, prolonged palliation for recurrent pelvic cancers, and increased resectability in selected patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683872     DOI: 10.1001/archsurg.1993.01420170067009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

1.  Hepatic preconditioning of doxorubicin in stop-flow chemotherapy: NF-kappaB/IkappaB-alpha pathway and expression of HSP72.

Authors:  Hui Lu; Zheng-Gang Zhu; Xue-Xin Yao; Ren Zhao; Chao Yan; Yi Zhang; Bing-Ya Liu; Hao-Ran Yin; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

2.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

3.  Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique.

Authors:  H J Wanebo; M A Chung; A I Levy; P S Turk; M P Vezeridis; J F Belliveau
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

4.  Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model.

Authors:  Satoru Murata; Hiroyuki Tajima; Gen-ichi Kusakai; Tatsuo Kumazaki; Yutaka Abe; Shiro Onozawa; Yasushige Komada; Yukihiro Kondo; Ryoji Kimata; Seiichiro Himeno; Mitsuo Satake
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

5.  Results of regional chemotherapy using the aortic stop-flow technique in advanced pancreatic carcinoma.

Authors:  Frank Meyer; Thomas Gebauer; Reinhard Grote; Jens Martens-Lobenhoffer; Karsten Ridwelski; Hans Lippert
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Pelvic resection of recurrent rectal cancer.

Authors:  H J Wanebo; R J Koness; M P Vezeridis; S I Cohen; D E Wrobleski
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

7.  Changes in pelvic and systemic platinum concentrations during negative-balance isolated pelvic perfusion: correlation between platinum concentration and method of administration in a pig model.

Authors:  Satoru Murata; Hiroyuki Tajima; Yutaka Abe; Shiro Onozawa; Fumio Uchiyama; Hiromitsu Hayashi; Ryoji Kimata; Kazuhiro Nomura
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-24       Impact factor: 4.322

8.  Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability.

Authors:  Stefano Guadagni; Giancarlo Palumbo; Giammaria Fiorentini; Marco Clementi; Luca Marsili; Aldo Victor Giordano; Francesco Masedu; Marco Valenti
Journal:  BMC Res Notes       Date:  2017-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.